Loading…
Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide)
Background To evaluate the efficacy of timolol-dorzolamide drops used to decrease aqueous outflow from the eye on the prolongation of the biological activity of intravitreal bevacizumab. Methods Thirty-eight eyes of 38 patients with macular edema (ME) following retinal vein obstruction (RVO) were en...
Saved in:
| Published in: | Graefe's archive for clinical and experimental ophthalmology 2009, Vol.247 (1), p.35-42 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c369t-9622e611f8e1cce32dba9382be526195b7b54f5efb4de2064cecbdccae1e31003 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c369t-9622e611f8e1cce32dba9382be526195b7b54f5efb4de2064cecbdccae1e31003 |
| container_end_page | 42 |
| container_issue | 1 |
| container_start_page | 35 |
| container_title | Graefe's archive for clinical and experimental ophthalmology |
| container_volume | 247 |
| creator | Byeon, Suk Ho Kwon, Oh W. Song, Ji Hun Kim, Sung Eun Park, Yong Sik |
| description | Background
To evaluate the efficacy of timolol-dorzolamide drops used to decrease aqueous outflow from the eye on the prolongation of the biological activity of intravitreal bevacizumab.
Methods
Thirty-eight eyes of 38 patients with macular edema (ME) following retinal vein obstruction (RVO) were enrolled. These patients were randomly assigned into 2 groups: timolol-dorzolamide drops twice daily (n = 19) or no eyedrops (control; n = 19). All patients received 1.25 mg (in 0.05 mL) of bevacizumab intravitreally and were examined before treatment, 1 week after injection, and then every 4 weeks after injection. For each patient, visual acuity (VA), intraocular pressure (IOP), and central retinal thickness (CRT) by optical coherence tomography (OCT) were recorded before injection and at each visit after injection. The mean CRT at each timepoint was considered to directly reflect the biological activities of bevacizumab at those times.
Results
The mean CRT measured by OCT showed a significant decrease 1 week after treatment in both groups, and this difference was maintained for a total of 9 weeks (paired t-test, |
| doi_str_mv | 10.1007/s00417-008-0917-1 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_230789163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1599355711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-9622e611f8e1cce32dba9382be526195b7b54f5efb4de2064cecbdccae1e31003</originalsourceid><addsrcrecordid>eNp1kEtLAzEUhYMoWqs_wI0MrnQxmpvMcyn1CQVdKLgLSeZOSZmZ1GSm2P56M7TgylUuOeeec_kIuQB6C5Tmd57SBPKY0iKmZRjggEwg4WmcU_Z1SCY0ZxAXnH2dkFPvlzTYeQrH5ASKrGBlVk7Iz7uzje0Wsje2i2wdSd2btek34-xNt2gwMl3vZPhzKJtI4Vpqsx1aqSK1iWS1HNay66PerowOuvwe0A4-qnDl0PtRuv4wbShp4gfrtraRranw5owc1bLxeL5_p-Tz6fFj9hLP355fZ_fzWPOs7OMyYwwzgLpA0Bo5q5QsecEUpiyDMlW5SpM6xVolFTKaJRq1qrSWCMgDJD4lV7vclbPhNN-LpR1cFyoF4zQvSsh4MMHOpJ313mEtVs600m0EUDGiFjvUIqAWI2oBYedyHzyoFqu_jT3bYGA7gw9St0D31_x_6i-JrIzh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230789163</pqid></control><display><type>article</type><title>Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide)</title><source>Springer Link</source><creator>Byeon, Suk Ho ; Kwon, Oh W. ; Song, Ji Hun ; Kim, Sung Eun ; Park, Yong Sik</creator><creatorcontrib>Byeon, Suk Ho ; Kwon, Oh W. ; Song, Ji Hun ; Kim, Sung Eun ; Park, Yong Sik</creatorcontrib><description>Background
To evaluate the efficacy of timolol-dorzolamide drops used to decrease aqueous outflow from the eye on the prolongation of the biological activity of intravitreal bevacizumab.
Methods
Thirty-eight eyes of 38 patients with macular edema (ME) following retinal vein obstruction (RVO) were enrolled. These patients were randomly assigned into 2 groups: timolol-dorzolamide drops twice daily (n = 19) or no eyedrops (control; n = 19). All patients received 1.25 mg (in 0.05 mL) of bevacizumab intravitreally and were examined before treatment, 1 week after injection, and then every 4 weeks after injection. For each patient, visual acuity (VA), intraocular pressure (IOP), and central retinal thickness (CRT) by optical coherence tomography (OCT) were recorded before injection and at each visit after injection. The mean CRT at each timepoint was considered to directly reflect the biological activities of bevacizumab at those times.
Results
The mean CRT measured by OCT showed a significant decrease 1 week after treatment in both groups, and this difference was maintained for a total of 9 weeks (paired t-test, <0.001). The mean CRT at 1 week post-injection showed no significant between-group difference (p = 0.781). At 5 weeks post-injection, the timolol-dorzolamide group showed a significantly smaller mean CRT than the control group (p = 0.032). The difference in mean CRT between the 2 groups disappeared, however, at 9 weeks post-injection (p = 0.462). In both groups, VA improved significantly 1 week after injection, and these changes were maintained to 9 weeks post-injection in both groups. The mean VA of the 2 groups showed no difference at any time.
Conclusions
Timolol-dorzolamide aqueous depressant drops may delay the elimination of intravitreal bevacizumab but clinical efficacy of the eyedrops have not been proven in this study.</description><identifier>ISSN: 0721-832X</identifier><identifier>EISSN: 1435-702X</identifier><identifier>DOI: 10.1007/s00417-008-0917-1</identifier><identifier>PMID: 18682969</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject><![CDATA[Administration, Topical ; Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - adverse effects ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Humanized ; Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - adverse effects ; Aqueous Humor - physiology ; Bevacizumab ; Diabetic Retinopathy - complications ; Diabetic Retinopathy - drug therapy ; Diabetic Retinopathy - pathology ; Drug Synergism ; Drug Therapy, Combination ; Female ; Humans ; Injections ; Intraocular Pressure - drug effects ; Macular Edema - drug therapy ; Macular Edema - etiology ; Macular Edema - pathology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Ophthalmology ; Retinal Disorders ; Retinal Vein Occlusion - complications ; Retinal Vein Occlusion - drug therapy ; Retinal Vein Occlusion - pathology ; Sulfonamides - administration & dosage ; Sulfonamides - adverse effects ; Thiophenes - administration & dosage ; Thiophenes - adverse effects ; Timolol - administration & dosage ; Timolol - adverse effects ; Treatment Outcome ; Visual Acuity - drug effects ; Vitreous Body]]></subject><ispartof>Graefe's archive for clinical and experimental ophthalmology, 2009, Vol.247 (1), p.35-42</ispartof><rights>Springer-Verlag 2008</rights><rights>Springer-Verlag 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-9622e611f8e1cce32dba9382be526195b7b54f5efb4de2064cecbdccae1e31003</citedby><cites>FETCH-LOGICAL-c369t-9622e611f8e1cce32dba9382be526195b7b54f5efb4de2064cecbdccae1e31003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18682969$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Byeon, Suk Ho</creatorcontrib><creatorcontrib>Kwon, Oh W.</creatorcontrib><creatorcontrib>Song, Ji Hun</creatorcontrib><creatorcontrib>Kim, Sung Eun</creatorcontrib><creatorcontrib>Park, Yong Sik</creatorcontrib><title>Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide)</title><title>Graefe's archive for clinical and experimental ophthalmology</title><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><description>Background
To evaluate the efficacy of timolol-dorzolamide drops used to decrease aqueous outflow from the eye on the prolongation of the biological activity of intravitreal bevacizumab.
Methods
Thirty-eight eyes of 38 patients with macular edema (ME) following retinal vein obstruction (RVO) were enrolled. These patients were randomly assigned into 2 groups: timolol-dorzolamide drops twice daily (n = 19) or no eyedrops (control; n = 19). All patients received 1.25 mg (in 0.05 mL) of bevacizumab intravitreally and were examined before treatment, 1 week after injection, and then every 4 weeks after injection. For each patient, visual acuity (VA), intraocular pressure (IOP), and central retinal thickness (CRT) by optical coherence tomography (OCT) were recorded before injection and at each visit after injection. The mean CRT at each timepoint was considered to directly reflect the biological activities of bevacizumab at those times.
Results
The mean CRT measured by OCT showed a significant decrease 1 week after treatment in both groups, and this difference was maintained for a total of 9 weeks (paired t-test, <0.001). The mean CRT at 1 week post-injection showed no significant between-group difference (p = 0.781). At 5 weeks post-injection, the timolol-dorzolamide group showed a significantly smaller mean CRT than the control group (p = 0.032). The difference in mean CRT between the 2 groups disappeared, however, at 9 weeks post-injection (p = 0.462). In both groups, VA improved significantly 1 week after injection, and these changes were maintained to 9 weeks post-injection in both groups. The mean VA of the 2 groups showed no difference at any time.
Conclusions
Timolol-dorzolamide aqueous depressant drops may delay the elimination of intravitreal bevacizumab but clinical efficacy of the eyedrops have not been proven in this study.</description><subject>Administration, Topical</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Aqueous Humor - physiology</subject><subject>Bevacizumab</subject><subject>Diabetic Retinopathy - complications</subject><subject>Diabetic Retinopathy - drug therapy</subject><subject>Diabetic Retinopathy - pathology</subject><subject>Drug Synergism</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Injections</subject><subject>Intraocular Pressure - drug effects</subject><subject>Macular Edema - drug therapy</subject><subject>Macular Edema - etiology</subject><subject>Macular Edema - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Ophthalmology</subject><subject>Retinal Disorders</subject><subject>Retinal Vein Occlusion - complications</subject><subject>Retinal Vein Occlusion - drug therapy</subject><subject>Retinal Vein Occlusion - pathology</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - adverse effects</subject><subject>Thiophenes - administration & dosage</subject><subject>Thiophenes - adverse effects</subject><subject>Timolol - administration & dosage</subject><subject>Timolol - adverse effects</subject><subject>Treatment Outcome</subject><subject>Visual Acuity - drug effects</subject><subject>Vitreous Body</subject><issn>0721-832X</issn><issn>1435-702X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp1kEtLAzEUhYMoWqs_wI0MrnQxmpvMcyn1CQVdKLgLSeZOSZmZ1GSm2P56M7TgylUuOeeec_kIuQB6C5Tmd57SBPKY0iKmZRjggEwg4WmcU_Z1SCY0ZxAXnH2dkFPvlzTYeQrH5ASKrGBlVk7Iz7uzje0Wsje2i2wdSd2btek34-xNt2gwMl3vZPhzKJtI4Vpqsx1aqSK1iWS1HNay66PerowOuvwe0A4-qnDl0PtRuv4wbShp4gfrtraRranw5owc1bLxeL5_p-Tz6fFj9hLP355fZ_fzWPOs7OMyYwwzgLpA0Bo5q5QsecEUpiyDMlW5SpM6xVolFTKaJRq1qrSWCMgDJD4lV7vclbPhNN-LpR1cFyoF4zQvSsh4MMHOpJ313mEtVs600m0EUDGiFjvUIqAWI2oBYedyHzyoFqu_jT3bYGA7gw9St0D31_x_6i-JrIzh</recordid><startdate>2009</startdate><enddate>2009</enddate><creator>Byeon, Suk Ho</creator><creator>Kwon, Oh W.</creator><creator>Song, Ji Hun</creator><creator>Kim, Sung Eun</creator><creator>Park, Yong Sik</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>2009</creationdate><title>Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide)</title><author>Byeon, Suk Ho ; Kwon, Oh W. ; Song, Ji Hun ; Kim, Sung Eun ; Park, Yong Sik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-9622e611f8e1cce32dba9382be526195b7b54f5efb4de2064cecbdccae1e31003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Administration, Topical</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Aqueous Humor - physiology</topic><topic>Bevacizumab</topic><topic>Diabetic Retinopathy - complications</topic><topic>Diabetic Retinopathy - drug therapy</topic><topic>Diabetic Retinopathy - pathology</topic><topic>Drug Synergism</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Injections</topic><topic>Intraocular Pressure - drug effects</topic><topic>Macular Edema - drug therapy</topic><topic>Macular Edema - etiology</topic><topic>Macular Edema - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Ophthalmology</topic><topic>Retinal Disorders</topic><topic>Retinal Vein Occlusion - complications</topic><topic>Retinal Vein Occlusion - drug therapy</topic><topic>Retinal Vein Occlusion - pathology</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - adverse effects</topic><topic>Thiophenes - administration & dosage</topic><topic>Thiophenes - adverse effects</topic><topic>Timolol - administration & dosage</topic><topic>Timolol - adverse effects</topic><topic>Treatment Outcome</topic><topic>Visual Acuity - drug effects</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Byeon, Suk Ho</creatorcontrib><creatorcontrib>Kwon, Oh W.</creatorcontrib><creatorcontrib>Song, Ji Hun</creatorcontrib><creatorcontrib>Kim, Sung Eun</creatorcontrib><creatorcontrib>Park, Yong Sik</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Byeon, Suk Ho</au><au>Kwon, Oh W.</au><au>Song, Ji Hun</au><au>Kim, Sung Eun</au><au>Park, Yong Sik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide)</atitle><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle><stitle>Graefes Arch Clin Exp Ophthalmol</stitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><date>2009</date><risdate>2009</risdate><volume>247</volume><issue>1</issue><spage>35</spage><epage>42</epage><pages>35-42</pages><issn>0721-832X</issn><eissn>1435-702X</eissn><abstract>Background
To evaluate the efficacy of timolol-dorzolamide drops used to decrease aqueous outflow from the eye on the prolongation of the biological activity of intravitreal bevacizumab.
Methods
Thirty-eight eyes of 38 patients with macular edema (ME) following retinal vein obstruction (RVO) were enrolled. These patients were randomly assigned into 2 groups: timolol-dorzolamide drops twice daily (n = 19) or no eyedrops (control; n = 19). All patients received 1.25 mg (in 0.05 mL) of bevacizumab intravitreally and were examined before treatment, 1 week after injection, and then every 4 weeks after injection. For each patient, visual acuity (VA), intraocular pressure (IOP), and central retinal thickness (CRT) by optical coherence tomography (OCT) were recorded before injection and at each visit after injection. The mean CRT at each timepoint was considered to directly reflect the biological activities of bevacizumab at those times.
Results
The mean CRT measured by OCT showed a significant decrease 1 week after treatment in both groups, and this difference was maintained for a total of 9 weeks (paired t-test, <0.001). The mean CRT at 1 week post-injection showed no significant between-group difference (p = 0.781). At 5 weeks post-injection, the timolol-dorzolamide group showed a significantly smaller mean CRT than the control group (p = 0.032). The difference in mean CRT between the 2 groups disappeared, however, at 9 weeks post-injection (p = 0.462). In both groups, VA improved significantly 1 week after injection, and these changes were maintained to 9 weeks post-injection in both groups. The mean VA of the 2 groups showed no difference at any time.
Conclusions
Timolol-dorzolamide aqueous depressant drops may delay the elimination of intravitreal bevacizumab but clinical efficacy of the eyedrops have not been proven in this study.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>18682969</pmid><doi>10.1007/s00417-008-0917-1</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0721-832X |
| ispartof | Graefe's archive for clinical and experimental ophthalmology, 2009, Vol.247 (1), p.35-42 |
| issn | 0721-832X 1435-702X |
| language | eng |
| recordid | cdi_proquest_journals_230789163 |
| source | Springer Link |
| subjects | Administration, Topical Adult Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antihypertensive Agents - administration & dosage Antihypertensive Agents - adverse effects Aqueous Humor - physiology Bevacizumab Diabetic Retinopathy - complications Diabetic Retinopathy - drug therapy Diabetic Retinopathy - pathology Drug Synergism Drug Therapy, Combination Female Humans Injections Intraocular Pressure - drug effects Macular Edema - drug therapy Macular Edema - etiology Macular Edema - pathology Male Medicine Medicine & Public Health Middle Aged Ophthalmology Retinal Disorders Retinal Vein Occlusion - complications Retinal Vein Occlusion - drug therapy Retinal Vein Occlusion - pathology Sulfonamides - administration & dosage Sulfonamides - adverse effects Thiophenes - administration & dosage Thiophenes - adverse effects Timolol - administration & dosage Timolol - adverse effects Treatment Outcome Visual Acuity - drug effects Vitreous Body |
| title | Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide) |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T13%3A51%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolongation%20of%20activity%20of%20single%20intravitreal%20bevacizumab%20by%20adjuvant%20topical%20aqueous%20depressant%20(Timolol-Dorzolamide)&rft.jtitle=Graefe's%20archive%20for%20clinical%20and%20experimental%20ophthalmology&rft.au=Byeon,%20Suk%20Ho&rft.date=2009&rft.volume=247&rft.issue=1&rft.spage=35&rft.epage=42&rft.pages=35-42&rft.issn=0721-832X&rft.eissn=1435-702X&rft_id=info:doi/10.1007/s00417-008-0917-1&rft_dat=%3Cproquest_cross%3E1599355711%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c369t-9622e611f8e1cce32dba9382be526195b7b54f5efb4de2064cecbdccae1e31003%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230789163&rft_id=info:pmid/18682969&rfr_iscdi=true |